Business Wire

Foundever ® and Cognigy Strengthen Strategic Partnership to Deliver Scalable Agentic AI Solutions Across the Globe

10.6.2025 15:00:00 EEST | Business Wire | Press release

Share

Foundever®, a global leader in the customer experience (CX) industry, today announced an expansion of its long-term collaboration with Cognigy, a global leader in AI-powered customer service solutions, in bringing Agentic AI into full-scale production across enterprise CX environments. This partnership addresses the increasing demand from global brands for sophisticated AI solutions that offer proactive, autonomous service, going beyond basic automation to deliver secure, scalable, personalized and human-centric interactions.

By integrating the large-scale and global operational capabilities of Foundever with Cognigy's powerful Agentic AI, this partnership redefines the possibilities of automation, exceeding the limitations of traditional chatbots. In a truly Agentic CX environment, Foundever ensures AI agents work seamlessly alongside humans to create a real, integrated experience across diverse customer journeys. With conversational design built on a depth of experience managing over 3.3 billion customer interactions each year, Foundever brings operational processes and training to empower both AI and human agents. Using data to drive continuous improvements across all aspects of the customer experience, the combined capabilities of Foundever and Cognigy connect data, technology and human expertise in ways that deliver unmatched value.

As organizations rush to incorporate AI, the truth is clear: simply showcasing impressive demos is not enough. Together, Foundever and Cognigy are bridging this gap while accelerating the transition of AI-powered CX into real-world applications, demonstrating tangible, measurable results. The proactive approach and strategic insight that Foundever brings into operationalizing AI technology highlights its role as both a beneficiary and a creator of substantial value. This partnership, already trusted by Fortune 500 brands worldwide, paves the way from innovative ideas to widespread enterprise implementation.

“At Foundever, we are dedicated to delivering solutions that provide real value at scale,” stated Laurent Uberti, President, CEO & Founder of Foundever. “Our collaboration with Cognigy is centered around deploying Agentic AI that operates effectively in production, at scale, and across various channels. Together, we’re establishing a new standard for what AI can achieve in customer interactions—enhancing CX while driving significant operational efficiencies. Our clients can expect not just advanced technology but also improved customer satisfaction, reduced operational costs and the ability to respond faster to market changes.”

As part of this partnership, Cognigy’s platform will integrate into the global CX operations of Foundever, enabling the deployment of multilingual, autonomous AI agents across both voice and digital channels. Built for adaptability, security and scalability, Cognigy empowers organizations to move beyond trial phases and embark on impactful, measurable transformations that yield substantial returns on investment. This expanded partnership is about delivering solutions that result in faster response times and improved customer engagement, ultimately driving growth for clients of Foundever and Cognigy.

“This expanded partnership with Foundever marks a pivotal step in bringing Agentic AI into real-world CX at scale,” said Philipp Heltewig, CEO and Co-founder at Cognigy. “We’ve already seen the value of combining Foundever’s global CX delivery with Cognigy’s AI Agent platform — and now we’re accelerating that impact. Together, we’re proving that AI Agents can do more than just automate — they can transform the way enterprises serve customers across channels, languages, and geographies.”

The partnership’s continued success was recognized at Nexus 2025, Cognigy’s flagship AI summit, where Foundever received the Most Unique Use Case award in the Innovation Champions category. With over 750 attendees from global brands, the event celebrated companies leveraging Cognigy’s AI Agents to deliver exceptional CX and tangible business impact.

With Foundever and Cognigy leading the charge, the future of AI-driven customer experience is here—powered by intelligent technology and a commitment to innovation. For more information on Foundever and its initiatives, visit foundever.com.

About Foundever

Foundever® is a global leader in the customer experience (CX) industry. With 150,000 associates across the globe, we’re the team behind the best experiences for +800 of the world’s leading and digital-first brands. Our innovative CX solutions, technology and expertise are designed to support operational needs for our clients and deliver a seamless experience to customers in the moments that matter.

Supporting +9 million customer conversations every day in +60 languages across 45 countries, Foundever combines global strength and scale with the agile, entrepreneurial approach of our founder-led culture, enabling companies of all sizes and industries to transform their CX. Sitel Group and SYKES are now Foundever.

Get to know us at www.foundever.com and connect with us on Facebook, LinkedIn and X.

About Cognigy

Cognigy is transforming the customer service industry with the most advanced AI Agent platform for enterprise contact centers. Its award-winning solution, Cognigy.AI, empowers enterprises to deliver instant, hyper-personalized, multilingual service on any channel. By integrating Generative and Conversational AI to create Agentic AI, Cognigy delivers AI Agents that redefine customer experiences, drive satisfaction, and support contact center employees in real-time. Over 1,000 brands worldwide trust Cognigy and its vast partner network to create AI customer service agents for their contact center. Cognigy's impressive worldwide customer portfolio includes Bosch, Nestlé, DHL, Frontier Airlines, Lufthansa Group, Mercedes-Benz and Toyota.

For more information and to book a demo visit: www.cognigy.com. Follow the company on X (formerly Twitter) @Cognigy and on LinkedIn at https://www.linkedin.com/company/cognigy.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250610379651/en/

Contacts

Media contacts
Rebecca Sanders, Foundever
media@foundever.com

Cognigy
Cognigy@avenuez.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye